Alung Technologies has received a Health Canada licence for its Hemolung respiratory assist system (RAS). The company has initiated commercialisation activities worldwide in preparation for a global launch of the system in 2013.
Hemolung RAS provides respiratory dialysis by removing carbon dioxide (CO2) and delivering oxygen directly to the blood, allowing a patient's lungs to rest and heal. The company completed a Europe-based clinical trial of the device in 2011 and has been working with regulators to secure market clearances.
Through its Hemolung reference centre programme, ALung will allow a select group of Canadian hospitals to have early access to the device before making it commercially available later this year. The company has also begun establishing European operations in anticipation of obtaining the CE mark, recently employing direct sales and clinical staff in Germany and the UK, and signing distributors in several other key European markets.
Hemolung RAS offers a minimally-invasive approach to extracorporeal carbon dioxide removal (ECCO2R) through use of a small venous catheter and techniques similar to renal dialysis. ALung believes that with Hemolung RAS, the company has developed a device that is very easy to use and provides clinically significant extracorporeal CO2 removal in a less-invasive way than existing extracorporeal gas exchange devices, such as extracorporeal membrane oxygenation.